Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute KaketsukenfiledCriticalChemo Sero Therapeutic Research Institute Kaketsuken
Publication of CA2046016A1publicationCriticalpatent/CA2046016A1/en
Application grantedgrantedCritical
Publication of CA2046016CpublicationCriticalpatent/CA2046016C/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Peptides Or Proteins
(AREA)
Abstract
A monoclonal antibody is described capable of binding to a glycoprotein antigen having a molecular weight of about 12 x 10 4 daltons (gp120) present in the envelope of human immunodeficiency virus (HIV) and capable of substantially neutralizing the HIV, or fragments thereof. It has the characteristics of immunoglobulin class IgG, k, being capable of binding to glycoprotein antigen having a molecular weight of 12 x 10 4 daltons (gp120) of HTLV-III MN, being capable of recognizing at least one epitope which is present in the region of the amino acid sequence 303 to 325 of gp120 of HTLV-III MN, being capable of binding to the surface of HTLV-III MN viral particles and thereby inhibiting the infection of the viral particles to CD4-positive cells, and being capable of binding to the surface of cells infected with HTLV-III MN and thereby inhibiting the syncytium formation induced by interaction between the infected cells and uninfected cells. The monoclonal antibody is useful for the prophylaxis, treatment and diagnosis of AIDS.
CA 20460161990-07-021991-06-28Hiv monoclonal antibody
Expired - Fee RelatedCA2046016C
(en)
Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities